SCHEMBL291194

SCHEMBL291194

O=C(O)CCCOCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.57
HDAC3 O15379 1/20 0.57
MAPK1 P28482 1/20 0.57
ADRA1A P35348 1/20 0.57
HDAC4 P56524 1/20 0.57
SLC6A3 Q01959 1/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC7 Q8WUI4 1/20 0.57
HDAC2 Q92769 1/20 0.57
HDAC10 Q969S8 1/20 0.57
HDAC11 Q96DB2 1/20 0.57
HDAC8 Q9BY41 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
HDAC9 Q9UKV0 1/20 0.57
HDAC5 Q9UQL6 1/20 0.57
HTT P42858 2/20 0.54
MAPT P10636 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
TSHR P16473 1/20 0.52
FOLH1 Q04609 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24756824 0.96 SMN1; SMN2 (0.53) SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4
SCHEMBL22367410 0.96 SMN1; SMN2 (0.53) SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4
SCHEMBL712393 0.94 MAPT (0.56) SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4
SCHEMBL24674898 0.93 MAPT (0.51) SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4
SCHEMBL2871485 0.93 MAPT (0.59) SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4
SCHEMBL830483 0.93 MAPT (0.59) SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4
SCHEMBL1007119 0.93 MAPT (0.59) SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4
SCHEMBL5508985 0.93 MAPT (0.59) SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4
SCHEMBL2867823 0.93 MAPT (0.59) SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4
SCHEMBL1008067 0.93 MAPT (0.59) SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 608 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117903094-A Process for preparing alpha-pyrone-polyketone 深圳乾延药物研发科技有限公司 2024-04-19 CN claimed
CN-111440046-B Synthetic method of sex pheromone (S) -14-methyl-1-octadecene of lepidoptera pest phyllocladia persica 塔里木大学 2022-09-16 CN claimed
CN-111440046-A Synthesis method of sex pheromone (S) -14-methyl-1-octadecene of lepidoptera pest peach leaf miner 塔里木大学 2020-07-24 CN claimed
EP-2727915-B1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS INC (US) 2016-04-13 EP claimed
EP-2727915-A1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof Concert Pharmaceuticals Inc. (US) 2014-05-07 EP claimed
US-20060040366-A1 New polyhydroxyalkanoate comprising unit having (phenylmethyl) oxy structure on side chain thereof, and method for producing the same CANON KABUSHIKI KAISHA (JP) 2006-02-23 US claimed
CN-122094963-A Cardioprotective lipids and methods of use 2026-05-26 CN disclosed
US-20260068886-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2026-03-12 US disclosed
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
US-20250367299-A1 GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM ZEVRA THERAPEUTICS INC (US) 2025-12-04 US disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 US disclosed
EP-4419513-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2025-08-27 EP disclosed
US-6043245-A FUNGICIDES FOR TREATING OR PREVENTING FUNGAL INFECTION, ESPECIALLY ASPERGILLUS, CANDIDA, CYRPTOCOCCUS AND OPPORTUNISTIC INFECTIONS SCHERING CORPORATION (US) 2000-03-28 US disclosed
WO-1999015522-A1 TETRAHYDROFURAN PHOSPHATE- AND HYDROXY ESTERS, AS PRODRUGS FOR THE CORRESPONDING ANTIFUNGAL AGENT SCHERING CORPORATION (US) 1999-04-01 WO disclosed
EP-0821001-A1 AMIDITE DERIVATIVES AND OLIGONUCLEOTIDE DERIVATIVES Drug Delivery System Institute, Ltd. (JP) 1998-01-28 EP disclosed
US-5036152-A Antiinflammatory HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1991-07-30 US disclosed
US-4888328-A Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids HOESCHST-ROUSSEL INCORPORATED (US) 1989-12-19 US disclosed
EP-0332129-A2 Alkoxy- and alkylamino-carbonylalkylphospholipids, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1989-09-13 EP disclosed
US-4424343-A Preparation of 1-N- ω-amino-α-hydroxyalkanoyl!kanamycin polysilylates and products BRISTOL MYERS COMPANY (US) 1984-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX SMN1; SMN2 2126/4885HDAC3 142/4885MAPK1 245/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB SMN1; SMN2 2586/4885HDAC3 1496/4885MAPK1 1866/4885
US-20250367299-A1 GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM HSD17B10, HSD17B12, HSD17B14 SMN1; SMN2 700/4885HDAC3 393/4885MAPK1 4721/4885
US-20260068886-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL CRBN, STUB1, CUL1 SMN1; SMN2 3771/4885HDAC3 1256/4885MAPK1 3126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.